No Data
No Data
William Blair Initiates NeoGenomics(NEO.US) With Buy Rating
NeoGenomics' Strategic Acquisition of Pathline: A Low-Risk Investment for Market Expansion and Growth
Craig-Hallum Maintains NeoGenomics(NEO.US) With Buy Rating
NeoGenomics (NEO) Gets a Buy From Craig-Hallum
NeoGenomics Expects Deal Accretive to Adj EBITDA Starting 2026 >NEO
Express News | Neogenomics Expands Oncology Testing Reach in the Northeast With Acquisition of Pathline
Unlock the Full List